Pneumagen is a privately held clinical phase company focusing on the development of Neumifil a pan-viral, pan-variant universal product for the prevention and treatment of exacerbation of disease due to viral respiratory infections such as influenza, RSV, COVID-19 and emerging pandemic viruses. Targeting glycans, Neumifil is a first-in-class intra-nasal product. Founded in 2016 from research conducted at the University of St. Andrews, the Company is focused on the further development of Neumifil and other Carbohydrate Binding Modules (CBMs) generated from our proprietary platform – GlycoTarge.